Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-Host Disease

Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children

Bone Marrow Transplantation volume 41, pages 571–577 (2008)Cite this article

Abstract

We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3–10 mg/m2 weekly. Seven of ten patients (70%) with aGVHD responded well to MTX, thus resulting in the achievement of either a complete response (CR) or a partial response (PR). The dose of prednisone could be reduced to equal to or lower than 1 mg/kg in the responding patients at the end of MTX therapy. The median number of MTX administrations was five (range, 1–7). Ten (58.8%) of seventeen patients with cGVHD achieved CR or PR. The dose of prednisone could be reduced to lower than 0.4 mg/kg in 16 of 17 patients and seven patients could discontinue prednisone. The median duration of MTX administration was 18 months (range, 1–68). The toxicities of grade III to IV occurred in only six patients presenting cytopenias or elevated levels of serum transaminases. Low-dose MTX was tolerable and effective for the steroid-refractory or -dependent GVHD in reducing the dose of steroid without increasing the risk of opportunistic infection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Armitage JO . Bone marrow transplantation. N Engl J Med 1994; 330: 827–838.

    Article  CAS  PubMed  Google Scholar 

  2. Vogelsang GB . How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196–1201.

    Article  CAS  PubMed  Google Scholar 

  3. Lee SJ, Vogelsang G, Flowers MED . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.

    Article  CAS  PubMed  Google Scholar 

  4. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821–1828.

    CAS  PubMed  Google Scholar 

  5. Arai S, Margolis J, Zaburak M, Anders V, Vogelsang GB . Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155–160.

    Article  PubMed  Google Scholar 

  6. Grim J, Chladek J, Martinkova J . Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic disease. Clin Pharmacokinet 2003; 42: 139–151.

    Article  CAS  PubMed  Google Scholar 

  7. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR . Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353–356.

    Article  CAS  PubMed  Google Scholar 

  8. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA . Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132: 830–835.

    Article  CAS  PubMed  Google Scholar 

  9. Boehm IB, Boehm GA, Bauer R . Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanism. Rheumatol Int 1998; 18: 59–62.

    Article  CAS  PubMed  Google Scholar 

  10. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB . Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved toxicity. Semin Arthritis Rheum 1998; 27: 277–292.

    Article  CAS  PubMed  Google Scholar 

  11. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long DG et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–1230.

    Article  CAS  PubMed  Google Scholar 

  12. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  13. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  14. Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Bherz DL et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383–4389.

    CAS  PubMed  Google Scholar 

  15. Giaccone L, Martin P, Carpenter P, Moravec C, Hooper H, Funke VAM et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 337–341.

    Article  CAS  PubMed  Google Scholar 

  16. Huang XJ, Jiang Q, Chen H, Xu L, Liu D, Chen Y et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 343–348.

    Article  CAS  PubMed  Google Scholar 

  17. Seitz M . Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999; 11: 226–232.

    Article  CAS  PubMed  Google Scholar 

  18. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-γ, and tumor necrosis factor-α in graft-versus-host disease. Bone Marrow Transplant 1994; 13: 745–751.

    CAS  PubMed  Google Scholar 

  19. Jacobsohn DA, Vogelsang GB . Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des 2004; 10: 1195–1205.

    Article  CAS  PubMed  Google Scholar 

  20. Ferrara JLM . Paradigm shift for graft-versus-host disease. Bone Marrow Transplant 1994; 14: 183–184.

    CAS  PubMed  Google Scholar 

  21. Ferrara JLM, Reddy P . Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3–10.

    Article  CAS  PubMed  Google Scholar 

  22. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  23. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host disease syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  24. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    CAS  PubMed  Google Scholar 

  25. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77–82.

    CAS  PubMed  Google Scholar 

  26. Khoury H, kashyap A, Adkins DR, Brown RA, Miller G, Vij R et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059–1064.

    Article  CAS  PubMed  Google Scholar 

  27. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O . Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147–153.

    Article  CAS  PubMed  Google Scholar 

  28. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367–374.

    Article  CAS  PubMed  Google Scholar 

  29. Couriel D, Saliba R, Hicks K, Ippoliti C, De Lima M, Hosing C et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004; 104: 649–654.

    Article  CAS  PubMed  Google Scholar 

  30. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768–2776.

    Article  CAS  PubMed  Google Scholar 

  31. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003–1010.

    Article  CAS  PubMed  Google Scholar 

  32. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J . Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84: 681–685.

    Article  CAS  PubMed  Google Scholar 

  33. Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661–2668.

    Article  CAS  PubMed  Google Scholar 

  34. Arora M, Burns LJ, Davies SM, MacMillan ML, Defor TE, Miller WJ et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003; 9: 38–45.

    Article  PubMed  Google Scholar 

  35. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102: 802–809.

    Article  CAS  PubMed  Google Scholar 

  36. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 307–313.

    Article  CAS  PubMed  Google Scholar 

  37. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756–762.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka, Japan

    J Inagaki, Y Nagatoshi, M Hatano, N Isomura & M Sakiyama

  2. Institute for Clinical Research, National Kyusyu Cancer Center, Fukuoka, Japan

    J Okamura

Authors
  1. J Inagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Nagatoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Isomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Sakiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Nagatoshi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inagaki, J., Nagatoshi, Y., Hatano, M. et al. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplant 41, 571–577 (2008). https://doi.org/10.1038/sj.bmt.1705922

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705922

Keywords

This article is cited by

Search

Advanced search

Quick links